SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

SELLAS to Present Phase 2 SLS009 Data at ASH 2026

SELLAS said it will present Phase 2 data on SLS009 with azacitidine and venetoclax in patients with AML previously treated with venetoclax. The release cites a 54% overall response rate and median overall survival of 5.8, but the supplied body is truncated and does not specify the survival unit.

SLS
SquawkNews Desk

Related stories

Air Travel Disruptions to Persist Into Sunday, Officials Say Officials say thousands of flights have been affected, with air travel issues expected to persist well into Sunday. M impact | EQUITY | Nov 14, 2026, 09:39 PM UTC SpaceX Starship Returns to Texas Launch Tower After Orbital Flight SpaceX’s Starship spacecraft returned Saturday to the Texas launch tower from which it launched a day earlier, completing the rocket system’s first key recovery, according to the r M impact | EQUITY | Nov 14, 2026, 09:22 PM UTC More Than 10,000 Flights Delayed or Canceled Saturday Airlines are working to restore normal schedules. M impact | EQUITY | Nov 14, 2026, 07:34 PM UTC Flight Cancellations Mount at DFW and Love Field After FAA Ground Stop Cancellations mounted Saturday morning at DFW International Airport and Dallas Love Field after an FAA ground stop was lifted. M impact | EQUITY | Nov 14, 2026, 07:03 PM UTC Thousands of US Flights Canceled and Delayed as Air Travel System Recovers Thousands of US flights were canceled or delayed as the air travel system slowly recovered from a shutdown. M impact | EQUITY | Nov 14, 2026, 06:37 PM UTC Lilly Phase 3 Trial Reports Average 21.4% BMI Reduction With Zepbound The SURMOUNT-ADOLESCENTS trial showed Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 with obesity. M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC